NCT06254911View on ClinicalTrials.gov

Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 27, 2023

Primary Completion Date

December 16, 2025

Study Completion Date

December 16, 2026

Conditions
Oropharynx Cancer, Stage I
Interventions
BIOLOGICAL

Atezolizumab

Given IV

PROCEDURE

Transoral Surgery with cervical lymphadenctomy (neck dissection)

Undergo definitive surgical treatment to remove cancer from the tonsil or tongue base combined with removal of the at risk lymph nodes in the neck

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (1)

30308

RECRUITING

Emory University Hospital Midtown, Atlanta

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Genentech, Inc.

INDUSTRY

lead

Emory University

OTHER